CAS: 4926-47-0; 3-Bromoimidazo[1,2-A]Pyridine

相似化合物

1263060-75-8 1263058-67-8 1065074-14-7

上下游产品

CAS号274-76-0 咪唑并[1,2-a]吡啶 | CAS号860257-98-3 N-(咪唑并[1,2-a]吡啶... | CAS号882562-65-4 3-(2,5-二氯嘧啶-4-基... | CAS号943320-53-4 3-炔基咪唑并[1,2-a]吡啶

2-氨基吡啶置于dipotassium Peroxodisulfate,Copper(L) Iodide,三氟化硼乙醚,Sodium Bromide体系中,用 二氯甲烷,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 48.0H,反应生成 3-溴咪唑[1,2-A]嘧啶
参考文献:咪唑基融合杂环卤化的钠盐(nai / Nabr / Nacl)
标题:咪唑基融合杂环卤化的钠盐(nai / Nabr / Nacl)
摘要:我们在此报告了一种使用容易获得的钠盐(nacl / Nabr / Nai)作为卤素源和k 2 S 2 O 8(或)oxone作为促进剂的咪唑基稠合杂环卤化的有效方法.以非常好或优异的产率获得了各种c-3卤代咪唑并[1,2-A]吡啶和苯并[d]咪唑并[2,1-B]噻唑.本发明的卤化方法还以中等至优异的产率扩展到2-氨基吡啶,2-氨基嘧啶,吲哚和异喹啉.
DOI:10.1021/acs.Joc.8B02637

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:US-8518952-B2
优先权日:2008-08-06
标题 :6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
发明人：BRAGANZA JOHN FREDERICK; COLLINS MICHAEL RAYMOND; KATH JOHN CHARLES; NINKOVIC SACHA; LI HUI; RICHTER DANIEL TYLER
权利人:BRAGANZA JOHN FREDERICK; COLLINS MICHAEL RAYMOND; KATH JOHN CHARLES; NINKOVIC SACHA; LI HUI; RICHTER DANIEL TYLER; PFIZER
摘要:The present invention is directed to compounds of formula (I), n nand pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

专利号:CN-112390823-B
优先权日:2019-08-19
标 题 :A kind of synthesis method of minodronic acid